Qualigen Therapeutics, Inc.
QLGN
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-moleculeā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.50
Price-2.72%
-$0.07
1Y
Price
Market Cap
$4.230m
Small
Price/Earnings 3y Avg5y Avg
0.4x
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$2.237m
-
1y CAGR-31.8%
3y CAGR-26.8%
5y CAGREarnings
-$6.981m
-13.3%
1y CAGR+25.7%
3y CAGR+14.9%
5y CAGREPS
-$11,628.74
-67195.9%
1y CAGR-22581.1%
3y CAGR-16933.3%
5y CAGRBook Value
-$1.652m
$3.963m
Assets$5.615m
Liabilities$3.617m
DebtDebt to Assets
91.3%
-0.6x
Debt to EBITDAFree Cash Flow
-$6.757m
-6.8%
1y CAGR+18.6%
3y CAGR+16.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company